vinodm

• Mishra, Vinod Kumar; Gedde-Dahl, Tobias; Remberger, Mats; Solvang, Grethe; Selvaag, Kristin Mill Lien & Fosseng, Arne [Vis alle 10 forfattere av denne artikkelen] (2025). Hospital at Home Following Allogeneic Hematopoietic Stem Cell Transplantation: An Economic Analysis. Healthcare. doi: 10.3390/healthcare13141648. Fulltekst i vitenarkiv Vis sammendrag

  Background: Advanced home care is becoming increasingly common for cancer patients and serves as a viable alternative to inpatient hospital care. The transition to home care is driven by both the rising costs of healthcare and evidence indicating better quality of care. This study aims to compare the costs of hospital-at-home treatment and in-hospital care for patients undergoing allo-HSCT. Methods: The cost analysis was conducted as a case–control study comparing the costs of allo-HSCT at home (HaH) to the costs of allo-HSCT for patients receiving in-hospital care (INH). The cost evaluation was conducted from the hospital’s perspective, which means that costs incurred outside the hospital setting were not included. Post-procedural costs for the first year after allo-HSCT included all readmissions and outpatient visits at Oslo University Hospital. Results: The cost for the peritransplant period could be reduced by up to 33% by treating allo-HSCT recipients at home instead of in the hospital. During the study period, 24% of the allo-HSCT recipients were treated at home, but our data from 2021 and 2022 indicate that at least a third of the patients scheduled for allo-HSCT are candidates for HaH. Conclusions: The findings demonstrate that patients in advanced home care experience significantly lower total costs compared to those receiving in-hospital treatment.

• Andresen, Brith; Mishra, Vinod Kumar; Lewandowska, Milena; Andersen, Jack Gunnar; Andersen, Marit Helen & Lindberg, Harald L [Vis alle 8 forfattere av denne artikkelen] (2017). In-hospital cost comparison between percutaneous pulmonary valve implantation and surgery. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 51(4), s. 747–753. doi: 10.1093/ejcts/ezw378. Fulltekst i vitenarkiv Vis sammendrag

  OBJECTIVES: Today, both surgical and percutaneous techniques are available for pulmonary valve implantation in patients with right ventricle outflow tract obstruction or insufficiency. In this controlled, non-randomized study the hospital costs per patient of the two treatment options were identified and compared. METHODS: During the period of June 2011 until October 2014 cost data in 20 patients treated with the percutaneous technique and 14 patients treated with open surgery were consecutively included. Two methods for cost analysis were used, a retrospective average cost estimate (overhead costs) and a direct prospective detailed cost acquisition related to each individual patient (patient-specific costs). RESULTS: The equipment cost, particularly the stents and valve itself was by far the main cost-driving factor in the percutaneous pulmonary valve group, representing 96% of the direct costs, whereas in the open surgery group the main costs derived from the postoperative care and particularly the stay in the intensive care department. The device-related cost in this group represented 13.5% of the direct costs. Length-of-stay-related costs in the percutaneous group were mean $3885 (1618) and mean $17 848 (5060) in the open surgery group. The difference in postoperative stay between the groups was statistically significant (P<0.001). CONCLUSIONS: Given the high postoperative cost in open surgery, the percutaneous procedure could be cost saving even with a device cost of more than five times the cost of the surgical device. Keywords: Congenital pulmonary heart disease • Innovative techniques • Cost analysis • In-hospital costs

• Schive, Simen Walberg; Foss, Aksel; Sahraoui, Afaf; Kloster-Jensen, Kristine; Hafsahl, Geir & Kvalheim, Gunnar [Vis alle 15 forfattere av denne artikkelen] (2017). Cost and clinical outcome of islet transplantation in Norway 2010-2015. Clinical Transplantation. ISSN 0902-0063. 31:e12871(1), s. 1–8. doi: 10.1111/ctr.12871. Fulltekst i vitenarkiv Vis sammendrag

  Islet transplantation is a minimally invasive β-cell replacement strategy. Islet transplantation is a reimbursed treatment in Norway. Here, we summarize the cost and clinical outcome of 31 islet transplantations performed at Oslo University Hospital (OUS) from January 2010 to June 2015. Patients were retrospectively divided into three groups. Thirteen patients received either one or two islet transplantation alone (ITA), while five patients received islet transplantation after previous solid organ transplantation. For the group receiving 2 ITA, Kaplan-Meier estimates show an insulin independence of 20% more than 4 years after their last transplantation. An estimated 70% maintain at least partial graft function, defined as fasting C-peptide >0.1 nmol L−1, and 47% maintain a HbA1c below 6.5% or 2 percent points lower than before ITA. For all groups combined, we estimate that 44% of the patients have a 50% reduction in insulin requirement 4 years after the initial islet transplantation. The average cost for an islet transplantation procedure was 347 297±60 588 NOK, or 35 424±6182 EUR, of which isolation expenses represent 34%. We hereby add to the common pool of growing experience with islet transplantation and also describe the cost of the treatment at our center.

• Mishra, Vinod Kumar; Fiane, Arnt E; Winsnes, Benny Adam; Geiran, Odd; Sørensen, Gro & Hagen, Terje P. [Vis alle 7 forfattere av denne artikkelen] (2016). Cardiac Replacement Therapies: Outcomes and Costs for Heart Transplantation versus Circulatory Assist. Scandinavian Cardiovascular Journal. ISSN 1401-7431. 51(1), s. 1–7. doi: 10.1080/14017431.2016.1196826. Fulltekst i vitenarkiv
• Dahle, Gry; Rein, Kjell Arne; Fiane, Arnt E; Fosse, Erik; Kushi, Ishtiaq & Hagen, Terje P. [Vis alle 7 forfattere av denne artikkelen] (2012). Innovative technology-transcatheter aortic valve implantation: Cost and reimbursement issues. Scandinavian Cardiovascular Journal. ISSN 1401-7431. 46(6), s. 345–352. doi: 10.3109/14017431.2012.724177. Fulltekst i vitenarkiv
• Mishra, Vinod Kumar; Fiane, Arnt E; Geiran, Odd; Sørensen, Gro; Khushi, Ishtiaq & Hagen, Terje P. (2012). Hospital costs fell as numbers of LVADs were increasing: experiences from Oslo University Hospital. Journal of Cardiothoracic Surgery. Aug(27). doi: 10.1186/1749-8090-7-76. Fulltekst i vitenarkiv Vis sammendrag

  Background The current study was undertaken to examine total hospital costs per patient of a consecutive implantation series of two 3rd generation Left Ventricle Assist Devices (LVAD). Further we analyzed if increased clinical experience would reduce total hospital costs and the gap between costs and the diagnosis related grouped (DRG)-reimbursement. Method Cost data of 20 LVAD implantations (VentrAssist™) from 2005-2009 (period 1) were analyzed together with costs from nine patients using another LVAD (HeartWare™) from 2009-June 2011 (period 2). For each patient, total costs were calculated for three phases - the pre-LVAD implantation phase, the LVAD implantation phase and the post LVAD implant phase. Patient specific costs were obtained prospectively from patient records and included personnel resources, medication, blood products, blood chemistry and microbiology, imaging and procedure costs including operating room costs. Overhead costs were registered retrospectively and allocated to the specific patient by predefined allocation keys. Finally, patient specific costs and overhead costs were aggregated into total hospital costs for each patient. All costs were calculated in 2011-prices. We used regression analyses to analyze cost variations over time and between the different devices. Results The average total hospital cost per patient for the pre-LVAD, LVAD and post-LVAD for period 1 was $ 585, 513 (range 132, 640- 1 247, 299), and the corresponding DRG- reimbursement (2009) was $ 143, 192 . The mean LOS was 54 days (range 12- 127). For period 2 the total hospital cost per patient was $ 413, 185 (range 314, 540- 622, 664) and the corresponding DRG- reimbursement (2010) was $ 136, 963. The mean LOS was 49 days (range 31- 93). The estimates from the regression analysis showed that the total hospital costs, excluding device costs, per patient were falling as the number of treated patients increased. The estimate from the trend variable was -14, 096 US$ (CI -3, 842 to -24, 349, p < 0.01). Conclusion There were significant reductions in total hospital costs per patient as the numbers of patients were increasing. This can possibly be explained by a learning effect including better logistics, selection and management of patients.

• Mishra, Vinod Kumar; Svennevig, Jan Ludvig; Bugge, Jan Frederik; Andresen, Sølvi; Mathisen, Agnete & Karlsen, Harald [Vis alle 8 forfattere av denne artikkelen] (2010). Cost of extracorporeal membrane oxygenation: evidence from Rikshospitalet University Hospital, Oslo, Norway. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 37(2), s. 339–342. doi: 10.1016/j.ejcts.2009.06.059. Fulltekst i vitenarkiv
• Mishra, Vinod Kumar; Geiran, Odd; Fiane, Arnt E; Sørensen, Gro; Andresen, Sølvi & Olsen, Ellen Kristin [Vis alle 8 forfattere av denne artikkelen] (2010). Costs and reimbursement gaps following implementation of 3rd generation Left Ventricular Assist Devices. The Journal of Heart and Lung Transplantation. ISSN 1053-2498. 29(1), s. 72–78. doi: 10.1016/j.healun.2009.06.029. Fulltekst i vitenarkiv Vis sammendrag

  BACKGROUND: The purpose of this study was to compare and contrast total hospital costs and subsequent reimbursement of implementing a new program using a third-generation left ventricular assist device (LVAD) in Norway. METHODS: Between July 2005 and March 2008, the total costs of treatment for 9 patients were examined. Costs were calculated for three periods—the pre-implantation LVAD phase, the LVAD implantation phase and the post-implantation LVAD phase—as well as for total hospital care. Patientspecific costs were obtained prospectively from patient records and included personnel resources, medication, blood products, blood chemistry and microbiology, imaging, and procedure costs including operating room costs. Overhead costs were registered retrospectively and allocated to the specific patient by pre-defined allocation keys. Finally, patient-specific costs and overhead costs were aggregated into total patient costs. RESULTS: The average total patient cost in 2007 U.S. dollars was $735,342 and the median was $613,087 (range $342,581 to $1,256,026). The mean length of stay was 77 days (range 40 to 127 days). For the LVAD implantation phase, the mean cost was $457,795 and median cost was $458,611 (range $246,239 to $677,680). The mean length of stay for the LVAD implantation phase was 55 days (range 25 to 125 days). The diagnosis-related group (DRG) reimbursement (2007) was $143,192. CONCLUSIONS: There is significant discrepancy between actual hospital costs and the current Norwegian DRG reimbursement for the LVAD procedure. This discrepancy can be partly explained by excessive costs related to the introduction of a new program with new technology. Costly innovations should be considered in price setting of reimbursement for novel technology.

• Mishra, Vinod Kumar; Geiran, Odd; Krohg-Sørensen, Kirsten & Andresen, S (2008). Thoracic aortic aneurysm repair. Direct hospital cost and Diagnosis Related Group reimbursement. Scandinavian Cardiovascular Journal. ISSN 1401-7431. 42, s. 77–84. doi: 10.1080/14017430701716814. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• Waldum, Åsa; Pay, Aase Serine Devold; Aasbø, Gunvor; Mishra, Vinod Kumar; Sugulle, Meryam & Staff, Anne Cathrine (2025). The HOME (home monitoring of high-risk pregnancies) study: a study protocol for an observational study of a telemedicine-assisted follow-up at home vs. hospitalization. doi: 10.3389/fgwh.2025.1599153. Fulltekst i vitenarkiv
• Ghimire, U.; Huang, S.; Shrestha, N.; Vetter, T.; Daggupati, P. & Mishra, V. [Vis alle 7 forfattere av denne artikkelen] (2020). Impacts of hydrological model calibration on projected hydrological changes under climate change – a multi-model assessment in three large river basins. Climatic Change. ISSN 0165-0009. 163, s. 1143–1164. doi: 10.1007/s10584-020-02872-6. Fulltekst i vitenarkiv Vis sammendrag

  This study aimed to investigate the influence of hydrological model calibration/validation on discharge projections for three large river basins (the Rhine, Upper Mississippi and Upper Yellow). Three hydrological models (HMs), which have been firstly calibrated against the monthly discharge at the outlet of each basin (simple calibration), were re-calibrated against the daily discharge at the outlet and intermediate gauges under contrast climate conditions simultaneously (enhanced calibration). In addition, the models were validated in terms of hydrological indicators of interest (median, low and high flows) as well as actual evapotranspiration in the historical period. The models calibrated using both calibration methods were then driven by the same bias corrected climate projections from five global circulation models (GCMs) under four Representative Concentration Pathway scenarios (RCPs). The hydrological changes of the indicators were represented by the ensemble median, ensemble mean and ensemble weighted means of all combinations of HMs and GCMs under each RCP. The results showed moderate (5–10%) to strong influence (> 10%) of the calibration methods on the ensemble medians/means for the Mississippi, minor to moderate (up to 10%) influence for the Yellow and minor (< 5%) influence for the Rhine. In addition, the enhanced calibration/validation method reduced the shares of uncertainty related to HMs for three indicators in all basins when the strict weighting method was used. It also showed that the successful enhanced calibration had the potential to reduce the uncertainty of hydrological projections, especially when the HM uncertainty was significant after the simple calibration.

• Bjørnelv, Gudrun Maria Waaler; Fretland, Åsmund Avdem; Edwin, Bjørn; Kristiansen, Ronny; Engvik, Linda & Mishra, Vinod Kumar [Vis alle 8 forfattere av denne artikkelen] (2016). COST-EFFECTIVENESS OF REPLACING OPEN LIVER RESECTION WITH LAPAROSCOPIC LIVER RESECTION FOR PATIENTS WITH COLORECTAL LIVER METASTASES. ANALYSES PERFORMED ALONGSIDE A RANDOMIZED CONTROLLED TRIAL: THE OSLO-COMET STUDY. Fulltekst i vitenarkiv
• Mishra, Vinod Kumar; Brinch, Lorentz; Ernst, Peter; Lønset, May Kristin; Tangen, Jon Magnus & Wikelund, Jenny [Vis alle 13 forfattere av denne artikkelen] (2009). Kostnadsstudie av høydosebehandling med autolog stamcellestøtte ved fire norske sentra. Helseøkonomisk forskningsprogram ved Universitetet i Oslo. ISSN 9788277562018. Fulltekst i vitenarkiv

Se alle arbeider i NVA